- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Conduct bioequivalence study: CDSCO Panel Tells Cipla on Arsenic Trioxide Oral Solution
New Delhi: In response to a proposal presented by drug major Cipla for manufacturing and marketing of the chemotherapeutic agent Arsenic Trioxide Oral Solution, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has opined the firm to conduct bioequivalence (BE) study and submit the report.
This came after the drug major Cipla presented its proposal for the manufacture and marketing of Arsenic Trioxide Oral Solution 1mg/ml-5ml (additional dosage form and Indication) along with therapeutic rationale and justification for Phase III clinical trial waiver and BE study protocol before the committee.
Arsenic trioxide is a chemotherapeutic agent used in the treatment of refractory or relapsed acute promyelocytic leukaemia in patients with prior retinoid and anthracycline chemotherapy.
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first-line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
Arsenic Trioxide is indicated for induction of remission and consolidation in patients with acute promyelocytic leukaemia (APL) who are refractory to or have relapsed from retinoid and anthracycline chemotherapy.
Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein PML/RAR-alpha. It is suspected that arsenic trioxide induces cancer cells to undergo apoptosis.
At the recent SEC meeting for Oncology and Hematology held on 25th July 2023, the expert panel reviewed the proposal for the manufacturer and market of Arsenic Trioxide Oral Solution 1mg/ml-5ml along with therapeutic rationale and justification for Phase III clinical trial waiver and BE study protocol before the committee.
The Committee noted that the product Arsenol (arsenic trioxide) solution for oral use is only 5mg in 5ml (1mg/ml) with the same indication being approved since 2008 in the Hongkong.
After detailed deliberation, the Committee recommended conducting BE study as per the protocol presented and the firm should submit BE study report for further consideration of Phase III clinical trial waiver.
Also Read:Glenmark Gets CDSCO Panel Nod to study Indacaterol, Glycopyrrolate,Mometasone Furoate FDC drug
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.